These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 34905456)

  • 1. iPrevent: Engaging youth as long-acting HIV prevention product co-researchers in Cape Town, South Africa.
    Hartmann M; Minnis AM; Krogstad E; Ndwayana S; Sindelo S; Atujuna M; O'Rourke S; Bekker LG; Montgomery ET
    Afr J AIDS Res; 2021 Dec; 20(4):277-286. PubMed ID: 34905456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment.
    Minnis AM; Atujuna M; Browne EN; Ndwayana S; Hartmann M; Sindelo S; Ngcwayi N; Boeri M; Mansfield C; Bekker LG; Montgomery ET
    J Int AIDS Soc; 2020 Jun; 23(6):e25528. PubMed ID: 32544303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives of South African youth in the development of an implant for HIV prevention.
    Krogstad EA; Atujuna M; Montgomery ET; Minnis A; Ndwayana S; Malapane T; Shapley-Quinn MK; Manenzhe K; Bekker LG; van der Straten A
    J Int AIDS Soc; 2018 Aug; 21(8):e25170. PubMed ID: 30152004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.
    Montgomery ET; Atujuna M; Krogstad E; Hartmann M; Ndwayana S; OʼRourke S; Bekker LG; van der Straten A; Minnis AM
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):542-550. PubMed ID: 30865050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Acting Injection and Implant Preferences and Trade-Offs for HIV Prevention Among South African Male Youth.
    Montgomery ET; Browne EN; Atujuna M; Boeri M; Mansfield C; Sindelo S; Hartmann M; Ndwayana S; Bekker LG; Minnis AM
    J Acquir Immune Defic Syndr; 2021 Jul; 87(3):928-936. PubMed ID: 33633031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring user and stakeholder perspectives from South Africa and Uganda to refine microarray patch development for HIV PrEP delivery and as a multipurpose prevention technology.
    Ismail A; Magni S; Katahoire A; Ayebare F; Siu G; Semitala F; Kyambadde P; Friedland B; Jarrahian C; Kilbourne-Brook M
    PLoS One; 2023; 18(8):e0290568. PubMed ID: 37651432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
    Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
    AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferences Among Physicians and Men Who Have Sex with Men (MSM) for a Long-Acting, Removable Implant for HIV Prevention: A Discrete Choice Study.
    Tagliaferri Rael C; Giguere R; Sutton S; Horn E; Schieffer RJ; Greene GJ; D'Aquila R; Bryndza Tfaily E; Kiser PF; Hope TJ
    AIDS Res Hum Retroviruses; 2022 Dec; 38(12):898-908. PubMed ID: 36178358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
    Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PrEP rollout in Africa: status and opportunity.
    Irungu EM; Baeten JM
    Nat Med; 2020 May; 26(5):655-664. PubMed ID: 32405065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Community-Informed Language to Promote HIV Pre-exposure Prophylaxis (PrEP) in Black LGBTQ Communities in Baltimore.
    Fields EL; Long A; Bademosi K; Granderson R; Schumacher CM; Chandran A; Kingon Y; Jennings JM
    AIDS Educ Prev; 2020 Apr; 32(2):152-168. PubMed ID: 32539478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled Trial.
    Kawichai S; Songtaweesin WN; Wongharn P; Phanuphak N; Cressey TR; Moonwong J; Vasinonta A; Saisaengjan C; Chinbunchorn T; Puthanakit T
    JMIR Mhealth Uhealth; 2022 Apr; 10(4):e25561. PubMed ID: 35451976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
    Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
    BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers.
    Krogstad EA; Montgomery ET; Atujuna M; Minnis AM; O'Rourke S; Ahmed K; Bekker LG; van der Straten A
    AIDS Patient Care STDS; 2019 Apr; 33(4):157-166. PubMed ID: 30932697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study.
    Poteat T; Malik M; van der Merwe LLA; Cloete A; Adams D; Nonyane BAS; Wirtz AL
    Lancet HIV; 2020 Dec; 7(12):e825-e834. PubMed ID: 32622370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
    Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
    Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.